PROTAMINE SULFATE
Clinical safety rating: safe
Animal studies have demonstrated safety
Protamine sulfate is a cationic protein that binds to heparin, an anionic anticoagulant, forming a stable complex that neutralizes heparin's anticoagulant activity. It also has mild anticoagulant properties of its own.
| Metabolism | Protamine sulfate is rapidly metabolized in the plasma, though the exact metabolic pathways are not fully characterized. It is thought to be cleared by the reticuloendothelial system. |
| Excretion | Primarily renal excretion (heparin-protamine complexes are cleared by the reticuloendothelial system; elimination is largely independent of renal function). <5% excreted unchanged in urine. |
| Half-life | Complex with heparin: 4–5 minutes (free protamine: 7.4 minutes). Clinically, the anticoagulant reversal effect is rapid but may be transient due to heparin rebound. |
| Protein binding | None significant; protamine binds to heparin, not plasma proteins. |
| Volume of Distribution | Approximately 5 L (0.07 L/kg) – limited to plasma volume due to positive charge and rapid binding to heparin. |
| Bioavailability | Not applicable; only administered intravenously. Bioavailability: 100% IV. |
| Onset of Action | Intravenous: immediate (<1 minute) neutralization of heparin. Subcutaneous: not applicable; must be given IV. |
| Duration of Action | Approximately 2 hours (depending on heparin dose and half-life). Heparin rebound may occur 1–2 hours after initial reversal. |
| Molecular Weight | 4500 - 5000 Da (average ~4600) |
1 mg IV per 100 units of heparin to be neutralized, administered slowly (not exceeding 5 mg/min) with continuous monitoring. Maximum single dose: 50 mg.
| Dosage form | Injectable |
| Renal impairment | No specific GFR-based adjustment. Use with caution in renal impairment due to potential accumulation; monitor coagulation parameters. |
| Liver impairment | No specific Child-Pugh based adjustment. Use with caution in severe hepatic impairment due to altered clotting factors. |
| Pediatric use | 1 mg IV per 100 units of heparin to be neutralized, administered slowly (over 1-3 minutes). Maximum: 50 mg per dose. Adjust based on heparin dose and aPTT. |
| Geriatric use | No specific dose adjustment. Use lower end of dosing range and monitor closely due to increased risk of bleeding and hypersensitivity reactions. |
| 1st trimester | Use only if clearly needed; animal studies show no risk but human studies inadequate. |
| 2nd trimester | Use only if clearly needed; no known fetal risk in animal studies. |
| 3rd trimester | Use with caution; risk of maternal hypotension, bradycardia, and pulmonary hypertension may affect placental perfusion. |
Clinical note
No significant drug interactions Can cause severe hypotension and anaphylaxis.
| Placental transfer | Protamine sulfate, due to its high molecular weight and positive charge, is unlikely to cross the placenta in significant amounts. No studies have been performed. |
| Breastfeeding | Protamine sulfate is a large protein that is unlikely to be excreted into breast milk in clinically significant amounts. However, data are limited. Use with caution in nursing mothers. |
■ FDA Black Box Warning
None
| Common Effects | Hypotension |
| Serious Effects |
Known hypersensitivity to protamineSevere adverse reaction to protamine in the past
| Precautions | Risk of hypersensitivity reactions including anaphylaxis, especially in patients with fish allergies, previous exposure to protamine, or vasectomized males, Hypotension and bradycardia may occur with rapid administration, May cause transient anticoagulation at high doses, Monitor coagulation parameters (e.g., activated clotting time) during administration |
| Food/Dietary | No known food interactions. Avoid concurrent use of anticoagulant foods (e.g., ginger, garlic, ginkgo) unless specified. |
Loading safety data…
| Lactation Rating |
| L3 - Limited Data |
| Teratogenic Risk | Protamine sulfate is a heparin antagonist derived from fish sperm; it is a large protein that does not cross the placenta in significant amounts. Animal reproduction studies have not been conducted. In humans, there are no adequate data on fetal risk. Use during pregnancy only if clearly needed. There is no known teratogenic risk in any trimester. |
| Fetal Monitoring | Monitor for signs of hypersensitivity reactions (e.g., urticaria, bronchospasm, hypotension) and anticoagulation reversal effects. Monitor coagulation parameters (aPTT, ACT) to assess heparin reversal. Fetal heart rate monitoring during administration if used in obstetric procedures. |
| Fertility Effects | No studies on fertility effects in humans. Animal studies have not been conducted. Based on mechanism, no direct effect on fertility is anticipated. |
| Clinical Pearls | Administer slow IV (max 5 mg/min) to avoid hypotension and bradycardia. Monitor aPTT or ACT closely; dose based on 1 mg per 100 units of heparin neutralization. Risk of anaphylaxis in vasectomy or infertile men. Have resuscitation equipment ready. |
| Patient Advice | You will receive this medication to reverse the effects of heparin. · Report any allergic reactions like rash, itching, or difficulty breathing immediately. · You may experience a sudden drop in blood pressure; notify staff if feeling dizzy. · This drug can rarely cause severe allergic reactions, especially if you have had a vasectomy or are infertile. · You will have frequent blood tests to monitor your clotting status. |